» Articles » PMID: 16251535

A MicroRNA Signature Associated with Prognosis and Progression in Chronic Lymphocytic Leukemia

Abstract

Background: MicroRNA expression profiles can be used to distinguish normal B cells from malignant B cells in patients with chronic lymphocytic leukemia (CLL). We investigated whether microRNA profiles are associated with known prognostic factors in CLL.

Methods: We evaluated the microRNA expression profiles of 94 samples of CLL cells for which the level of expression of 70-kD zeta-associated protein (ZAP-70), the mutational status of the rearranged immunoglobulin heavy-chain variable-region (IgV(H) ) gene, and the time from diagnosis to initial treatment were known. We also investigated the genomic sequence of 42 microRNA genes to identify abnormalities.

Results: A unique microRNA expression signature composed of 13 genes (of 190 analyzed) differentiated cases of CLL with low levels of ZAP-70 expression from those with high levels and cases with unmutated IgV(H) from those with mutated IgV(H) . The same microRNA signature was also associated with the presence or absence of disease progression. We also identified a germ-line mutation in the miR-16-1-miR-15a primary precursor, which caused low levels of microRNA expression in vitro and in vivo and was associated with deletion of the normal allele. Germ-line or somatic mutations were found in 5 of 42 sequenced microRNAs in 11 of 75 patients with CLL, but no such mutations were found in 160 subjects without cancer (P<0.001).

Conclusions: A unique microRNA signature is associated with prognostic factors and disease progression in CLL. Mutations in microRNA transcripts are common and may have functional importance.

Citing Articles

The mutational landscape and functional effects of noncoding ultraconserved elements in human cancers.

Bayraktar R, Tang Y, Dragomir M, Ivan C, Peng X, Fabris L Sci Adv. 2025; 11(8):eado2830.

PMID: 39970212 PMC: 11837999. DOI: 10.1126/sciadv.ado2830.


BCL-2 inhibitors in hematological malignancies: biomarkers that predict response and management strategies.

Markouli M, Pagoni M, Diamantopoulos P Front Oncol. 2025; 14:1501950.

PMID: 39906657 PMC: 11790632. DOI: 10.3389/fonc.2024.1501950.


MicroRNAs Expression Profile in MN1-Altered Astroblastoma.

Gianno F, Miele E, Sabato C, Ferretti E, Minasi S, Buttarelli F Biomedicines. 2025; 13(1).

PMID: 39857696 PMC: 11762140. DOI: 10.3390/biomedicines13010112.


Investigating the association of microRNA polymorphisms and lifestyle factors with the susceptibility to common gastrointestinal cancers in an Indian population- A case control study.

Walter C, Shankaran Z, Kontham S, Ramachandran K, Prakash N, Johnson T Heliyon. 2025; 11(1):e41519.

PMID: 39850417 PMC: 11755044. DOI: 10.1016/j.heliyon.2024.e41519.


Crosstalk between non-coding RNAs and programmed cell death in colorectal cancer: implications for targeted therapy.

Taha S, Karimi M, Mahdavi B, Yousefi Tehrani M, Bemani A, Kabirian S Epigenetics Chromatin. 2025; 18(1):3.

PMID: 39810224 PMC: 11734566. DOI: 10.1186/s13072-024-00560-8.